Be Biopharma, Inc. ("Be Bio" or "the Company"), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round includes participation from new investor ...

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and ...

RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, secured Series A financing of $86 million ...

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s ...

The initial funding was led by Arch Venture Partners, F-Prime Capital and Mubadala Capital with participation from other unnamed investors, according to a Jan. 8 release. Tenvie did not specify ...

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners, revealed a net loss of $156.26 million in the first nine months of 2024, compared to a ...

JPMorgan event follows the murder of an industry leader and the nomination of a vaccine sceptic as top official ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

The terms of the IPO were not disclosed in the offering. The San Francisco, California-based company is also backed by healthcare investors ARCH Venture Partners and General Catalyst. Maze is ...